05/23/22 8:47 AMNasdaq : CYTO low floatAltamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal SprayAltamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that Bentrio™ has been approved by the Philippines' Food and Drug Administration (FDA) and is nowRHEA-AIneutral
05/20/22 9:00 AMNasdaq : CYTO clinical triallow floatAltamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite StudyAltamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developingRHEA-AIneutral
05/19/22 9:00 AMNasdaq : CYTO conferenceslow floatAltamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment ConferenceAltamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it is scheduled to present virtually at the H.C. Wainwright Global Investment Conference, beingRHEA-AIneutral
05/18/22 8:47 AMNasdaq : CYTO low floatAltamira Therapeutics Issues Shareholder LetterAltamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medicalRHEA-AIneutral
05/05/22 8:47 AMNasdaq : CYTO covid-19low floatAltamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North MacedoniaAltamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeuticsRHEA-AIneutral
04/19/22 9:00 AMNasdaq : CYTO covid-19low floatAltamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that that it has reached the midpoint for enrollment in its COVAMID clinical investigation of itsRHEA-AIneutral
04/12/22 7:30 AMNasdaq : CYTO earningslow floatAltamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial ResultsSemaPhore™ platform for extrahepatic RNA deliver Established new business unit, OTC Consumer Health, to support global commercialization of Bentrio nasalRHEA-AIneutral
04/11/22 8:47 AMNasdaq : CYTO low floatAltamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta VariantSafety of Bentrio(TM) for Delta Variant Prophylactic treatment of human nasal mucosa with Bentrio™ was reported to significantly reduce the viral titer vs. controls over 4 days, reaching a maximum reduction of 99% with the wild-type SARS-CoV-2 variant and moreRHEA-AIneutral
04/04/22 8:47 AMNasdaq : CYTO earningslow floatAltamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ETAltamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it will hold an investor call on Tuesday, April 12, 2022, 8:00 a.m. ET to discuss its full-year 2021RHEA-AIneutral
03/15/22 9:00 AMNasdaq : CYTO low floatAltamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with BentrioAltamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced completion of patient enrollment in its Bentrio™ trial in house dust mite ("HDM") allergic rhinitis.RHEA-AIneutral